Literature DB >> 21804085

Raised serum creatinine at presentation does not adversely affect steroid response in primary focal segmental glomerulosclerosis in adults.

Nazrul Jafry1, Ejaz Ahmed, Muhammed Mubarak, Javed Kazi, Fazal Akhter.   

Abstract

BACKGROUND: There is no information in international literature on the mode of presentation, laboratory and clinical features, treatment and prognosis of primary focal segmental glomerulosclerosis (FSGS) in adults in Pakistan.
METHODS: This is a retrospective review of 124 adults (≥17 years) with a diagnosis of primary FSGS who presented to the adult nephrology clinic at Sindh Institute of Urology and Transplantation between January 1995 and June 2006. The clinical records and biopsy reports were reviewed to determine the demographic, clinical, laboratory and pathologic features, treatment responses and outcome of the disease. Renal biopsies were performed and evaluated by light microscopy, immunofluorescence and electron microscopy. Standard therapeutic regimens and response to therapy definitions were used. Outcome data were obtained at last follow-up.
RESULTS: Mean age of all patients was 30.9 ± 13.6 years (range: 17-85 years). Of these, 86 (69%) were males and 38 (31%) females, with a male to female ratio of 2.2:1. Of 124 patients, 79 (63.7%) were treated with steroids for a median duration of 5 months. Remission was achieved in 40 (50.6%) patients. Relapse occurred in 14 (17.7%) steroid-treated patients. These achieved sustained remission with retreatment. None of the steroid-treated patients went into end-stage renal disease over a mean follow-up of 2.3 years.
CONCLUSIONS: Results from this study show that half of adults with primary FSGS achieve sustained remission with prolonged steroid treatment and consequently exhibit an excellent prognosis for long-term outcome. Moreover, raised serum creatinine at presentation does not in itself adversely affect steroid response in adults with primary FSGS.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21804085     DOI: 10.1093/ndt/gfr430

Source DB:  PubMed          Journal:  Nephrol Dial Transplant        ISSN: 0931-0509            Impact factor:   5.992


  6 in total

Review 1.  Available and incoming therapies for idiopathic focal and segmental glomerulosclerosis in adults.

Authors:  Mirco Belingheri; Gabriella Moroni; Piergiorgio Messa
Journal:  J Nephrol       Date:  2017-05-03       Impact factor: 3.902

2.  Journal of Nephropathology: A need of the hour.

Authors:  Muhammed Mubarak
Journal:  J Nephropathol       Date:  2012-04-05

Review 3.  Focal Segmental Glomerulosclerosis.

Authors:  Avi Z Rosenberg; Jeffrey B Kopp
Journal:  Clin J Am Soc Nephrol       Date:  2017-02-27       Impact factor: 8.237

4.  Glucocorticoids in the treatment of patients with primary focal segmental glomerulosclerosis and moderate proteinuria.

Authors:  Jianni Huang; Li Lin; Jingyuan Xie; Xiao Li; Pingyan Shen; Xiaoxia Pan; Hong Ren; Nan Chen
Journal:  Clin Exp Nephrol       Date:  2018-05-14       Impact factor: 2.801

5.  Efficacy and Safety of Immunosuppressive Therapy in Primary Focal Segmental Glomerulosclerosis: A Systematic Review and Meta-analysis.

Authors:  Dawn J Caster; Barbara Magalhaes; Natali Pennese; Andrea Zaffalon; Marina Faiella; Kirk N Campbell; Jai Radhakrishnan; Vladmir Tesar; Howard Trachtman
Journal:  Kidney Med       Date:  2022-06-11

Review 6.  Treatment Strategies of Adult Primary Focal Segmental Glomerulosclerosis: A Systematic Review Focusing on the Last Two Decades.

Authors:  Arno Beer; Gert Mayer; Andreas Kronbichler
Journal:  Biomed Res Int       Date:  2016-04-07       Impact factor: 3.411

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.